Rhythm Pharmaceuticals (RYTM) announced that the United Kingdom’s Medicines & Healthcare products Regulatory Agency has expanded the marketing authorization for Imcivree to include the treatment of obesity and control of hunger associated with genetically confirmed Bardet-Biedl syndrome or genetically confirmed loss-of-function biallelic pro-opiomelanocortin, including proprotein convertase subtilisin/kexin type 1, deficiency or biallelic leptin receptor deficiency in adult and pediatric patients as young as 2 years old and older.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RYTM:
- Rhythm Pharmaceuticals announces five presentations at ESPE 2024
- Rhythm announces publication of setmelanotide Phase 3 results in The Lancet
- Rhythm Pharmaceuticals price target raised to $80 from $53 at Wells Fargo
- Rhythm Pharmaceuticals price target raised to $69 from $64 at H.C. Wainwright
- Rhythm Pharmaceuticals’ Common Stock Faces Risks from Convertible Preferred Stock Supremacy